News
DMK
0.4926
-3.35%
-0.0171
Weekly Report: what happened at DMK last week (1120-1124)?
Weekly Report · 1d ago
Weekly Report: what happened at DMK last week (1113-1117)?
Weekly Report · 11/20 10:01
DMK Pharmaceuticals Corporation: Current report
Press release · 11/16 04:25
DMK Pharmaceuticals Corporation: Quarterly report
Press release · 11/15 19:29
DMK Pharmaceuticals GAAP EPS of -$0.20
Dmk pharmaceuticals reports q3 gaap eps of -$0.20. Cash and cash equivalents as of september 30, 2023, were approximately $6.7 million. Dmk has a market value of approximately $1.2 billion. The company posted a q3 loss of $0.16 per share.
Seeking Alpha · 11/14 12:45
DMK Pharmaceuticals Q3 EPS $(0.20) Up From $(2.05) YoY, Sales $9.06K Down From $1.51M YoY
Dmk pharmaceuticals reported quarterly losses of $0.20 per share. The company reported $9.06 million in sales for the quarter. This is a 99.40 percent decrease over sales of $1.51 million the same period last year. Dmk reported losses of 90.24 percent.
Benzinga · 11/14 12:35
DMK Pharmaceuticals Announces Presentation Of Preclinical Results Comparing Effects Of DPI-125 On Opioid Withdrawal Behaviors Versus Standard Of Care For Opioid Use Disorder At SfN Neuroscience 2023
Preclinical results compare effects of dpi-125 on opioid withdrawal behaviors to methadone and buprenorphine. Preclinical results will be presented at the society for neuroscience annual meeting in 2023. Dmk is developing a novel opioid receptor agonist for the treatment of opioid use disorder.
Benzinga · 11/13 15:53
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Senestech (nasdaq:snes) stock is rocketing more than 70% alongside heavy pre-market trading. Collective audience shares are surging over 48% without any clear news this morning. A public offering, clinical trial results and more are moving shares on monday morning. 10 top pre- market stock movers: 10 biggest gainers and losers.
Investorplace · 11/13 12:29
Weekly Report: what happened at DMK last week (1106-1110)?
Weekly Report · 11/13 09:58
Weekly Report: what happened at DMK last week (1030-1103)?
Weekly Report · 11/06 10:00
Weekly Report: what happened at DMK last week (1023-1027)?
Weekly Report · 10/30 10:08
Weekly Report: what happened at DMK last week (1016-1020)?
Weekly Report · 10/23 10:03
DMK Pharmaceuticals Corporation: Current report
Press release · 10/20 03:13
DMK Pharmaceuticals announces appointment of Seth Cohen as CFO, succeeding David Marguglio
Seeking Alpha · 10/19 20:49
DMK Pharmaceuticals Restructures Executive Team To Support Next Phase Of Growth; Seth Cohen Is Appointed Chief Financial Officer
Benzinga · 10/19 20:12
More
Webull provides a variety of real-time DMK stock news. You can receive the latest news about DMK Pharmaceuticals Corporation through multiple platforms. This information may help you make smarter investment decisions.
About DMK
DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.